Page last updated: 2024-11-13

thrombin aptamer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

thrombin aptamer: nucleotide sequence given in first source; a synthetic polynucleotide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID156963293
MeSH IDM0217793

Synonyms (1)

Synonym
thrombin aptamer

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"To characterize the pharmacokinetic and tissue distribution profiles of a nucleotide-based thrombin inhibitor (GS522, phosphodiester oligonucleotide, GGTTGGTGTGGTTGG) following intravenous administration to rats."( Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats.
Reyderman, L; Stavchansky, S, 1998
)
0.3
"The pharmacokinetic and biodistribution profiles of GS522 following intravenous administration to rats at three doses were characterized."( Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats.
Reyderman, L; Stavchansky, S, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" There was a linear dose-response relationship between thrombin aptamer infusion rate and prolongation of plasma prothrombin time."( In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits.
Bock, LC; Griffin, LC; Leung, LL; Tidmarsh, GF; Toole, JJ, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (406)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (3.20)18.2507
2000's64 (15.76)29.6817
2010's289 (71.18)24.3611
2020's40 (9.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews11 (2.68%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other399 (97.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]